Use of palmitoylethanolamide in carpal tunnel syndrome: a prospective randomized study
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- 68 patients with carpal tunnel syndrome enrolled. 61 completed (30 on palmitoylethanolamide, 31 on placebo).
- Dose used in the study
- 300 mg twice a day
- Duration
- 60 days
- What was measured
- Levine's symptom and function questionnaire, Durkan's and Phalen's clinical tests, pain on a visual analogue scale, and nerve conduction tests
What the authors reported
Pain scores fell by 0.5 points on palmitoylethanolamide and 0.8 points on placebo. Neither group showed a statistically significant improvement on the clinical tests or the nerve conduction tests, though questionnaire scores improved in both groups. No complications from the medication were recorded.
Limits of this study
The trial found no advantage over placebo on its objective measures. The authors suggest that studies of higher doses are needed. The funding statement was not visible on the page checked.
Source
Entry checked against the article page at the publisher (Springer), with the citation from Crossref on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.